146 related articles for article (PubMed ID: 19175937)
1. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
[TBL] [Abstract][Full Text] [Related]
2. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Budman DR; Calabro A
Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
Fehm T; Zwirner M; Wallwiener D; Seeger H; Neubauer H
BMC Cancer; 2012 Jul; 12():308. PubMed ID: 22824103
[TBL] [Abstract][Full Text] [Related]
5. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study.
Elsayed M; Kobayashi D; Kubota T; Matsunaga N; Murata R; Yoshizawa Y; Watanabe N; Matsuura T; Tsurudome Y; Ogino T; Ohdo S; Shimazoe T
Biol Pharm Bull; 2016 Aug; 39(8):1238-46. PubMed ID: 27181081
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
Göbel A; Zinna VM; Dell'Endice S; Jaschke N; Kuhlmann JD; Wimberger P; Rachner TD
BMC Cancer; 2020 Jul; 20(1):703. PubMed ID: 32727400
[TBL] [Abstract][Full Text] [Related]
10. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ
Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.
Abdullah MI; Abed MN; Richardson A
Sci Rep; 2017 Aug; 7(1):8090. PubMed ID: 28808351
[TBL] [Abstract][Full Text] [Related]
12. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
Invest New Drugs; 2012 Aug; 30(4):1750-5. PubMed ID: 21604021
[No Abstract] [Full Text] [Related]
15. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
[TBL] [Abstract][Full Text] [Related]
16. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
Pathol Oncol Res; 2018 Jul; 24(3):557-565. PubMed ID: 28744693
[TBL] [Abstract][Full Text] [Related]
17. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
[TBL] [Abstract][Full Text] [Related]
18. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
19. Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms.
Kanugula AK; Gollavilli PN; Vasamsetti SB; Karnewar S; Gopoju R; Ummanni R; Kotamraju S
FEBS J; 2014 Aug; 281(16):3719-38. PubMed ID: 24964743
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
